The Court of Justice of the European Union (CJEU) last week handed down a preliminary ruling rejecting drugmaker Abraxis’ argument that its cancer drug Abraxane (paclitaxel protein-bound) should ...

Abraxane has been rejected by NICE for use in previously untreated metastatic pancreatic cancer. England's cost effectiveness watchdog says Celgene's Abraxane (nab-paclitaxel), which is taken with ...

ABRAXANE is a unique formulation of paclitaxel with a mean particle size of approximately 130 nanometers, that uses the natural properties of a human protein, albumin, to deliver the drug more ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update for paclitaxel formulations, highlighting the risk of medication error ...

Celgene’s Abraxane (nab-paclitaxel) is no better at treating metastatic pancreatic cancer than currently available treatments – but it is more expensive than them, according to NICE. In draft guidance ...

Makers of generic drugs in India are expected to start producing local versions of Celgene's ($CELG) oncology drug Abraxane after a consecutive denial of a patent. On ...

Sandoz has launched a generic paclitaxel formulation. It is the first generic of Abraxis BioScience’s (a Bristol Myers Squibb Co.) Abraxane to be approved by the Food and Drug Administration. Sandoz ...

Abraxane plus gemcitabine was superior to gemcitabine alone with statistically significant and clinically meaningful results across primary and key secondary endpoints and patient subgroups Oral ...